Business of the House

Mary Glindon Excerpts

Thursday 22nd October 2015 Commons Chamber

[Chris Grayling]

I congratulate my hon. Friend on being such an effective champion of equality in this House. I was not aware of international men’s day, but I will look very carefully at the suggestion he makes.

[Mary Glindon (North Tyneside) (Lab)]

The draft guidance released by the National Institute for Health and Care Excellence not to approve Translarna was devastating news for the boys with Duchenne muscular dystrophy who need still to be able to walk in order to access the treatment. Will the Leader of the House seek a statement from the Department of Health, or even allocate time for a debate, on Translarna?

[Chris Grayling]

It is always a difficult balance when new drugs come on stream. The role of NICE is to evaluate whether such drugs really can make the difference that is sometimes suggested by those producing them. That can often lead to very difficult, unhappy and challenging decisions. We, as politicians, are not really in a position to judge the rights and the wrongs of the effectiveness of drugs. What I will always do is ensure that such concerns are raised with my right hon. Friend the Secretary of State, so that he is aware of them. I am only too well aware of what a terrible disease this is. A number of children in my constituency are affected and, like the hon. Lady, I want them to receive the best possible treatment, but of course NICE has to take difficult decisions as well.